137,194 Shares in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Acquired by PVG Asset Management Corp

PVG Asset Management Corp bought a new stake in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 137,194 shares of the company’s stock, valued at approximately $295,000. Checkpoint Therapeutics accounts for about 1.2% of PVG Asset Management Corp’s portfolio, making the stock its 22nd biggest holding. PVG Asset Management Corp owned about 0.38% of Checkpoint Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in shares of Checkpoint Therapeutics during the 2nd quarter valued at $34,000. 180 Wealth Advisors LLC purchased a new stake in shares of Checkpoint Therapeutics in the second quarter worth about $96,000. Choreo LLC boosted its position in shares of Checkpoint Therapeutics by 200.9% in the first quarter. Choreo LLC now owns 57,922 shares of the company’s stock valued at $119,000 after acquiring an additional 38,672 shares during the period. B. Riley Wealth Advisors Inc. boosted its position in shares of Checkpoint Therapeutics by 232.3% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 163,350 shares of the company’s stock valued at $374,000 after acquiring an additional 114,200 shares during the period. Finally, Vanguard Group Inc. grew its stake in Checkpoint Therapeutics by 67.4% during the first quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock valued at $1,882,000 after acquiring an additional 369,586 shares in the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Checkpoint Therapeutics in a report on Monday, September 16th.

Checkpoint Therapeutics Stock Down 0.4 %

Checkpoint Therapeutics stock opened at $2.24 on Tuesday. The business has a 50-day simple moving average of $2.30 and a 200 day simple moving average of $2.04. Checkpoint Therapeutics, Inc. has a 52 week low of $1.36 and a 52 week high of $3.62. The stock has a market cap of $79.94 million, a price-to-earnings ratio of -0.81 and a beta of 1.29.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.11. The business had revenue of $0.04 million for the quarter. On average, research analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.81 earnings per share for the current year.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.